Phosphodiesterase Type 5 (pde5) - Pharma

Relevant Publications

Sildenafil amplifies calcium influx and insulin secretion in pancreatic β cells.

Issue Release: 2024

Sildenafil prevents chronic psychosocial stress-induced working memory impairment: Role of brain-derived neurotrophic factor.

Issue Release: 2024

Differences in Ocular Adverse Events Associated with phosphodiesterase-5 inhibitors: a real-world pharmacovigilance study.

Issue Release: 2024

The Association between PDE5 Inhibitors and Aneurysm/Arterial Dissection:A Pharmacovigilance Study Using WHO Safety Database.

Issue Release: 2024

Sildenafil, alone and in combination with imipramine or escitalopram, display antidepressant-like effects in an adrenocorticotropic hormone-induced (ACTH) rodent model of treatment-resistant depression.

Issue Release: 2024

Evaluation of platelet-rich fibrin matrix combined with PGE-1 injection on erectile function in patients with refractory response to PDE5-I: a randomized placebo-controlled study.

Issue Release: 2024

Successful treatment of hard flaccid syndrome with multimodal therapy: a case report study.

Issue Release: 2024

Measurement of PDE5 concentration in human serum: proof-of-concept and validation of methodology in control and prostate cancer patients.

Issue Release: 2024

Multimodal action of phosphodiesterase 5 inhibitors against neurodegenerative disorders: An update review.

Issue Release: 2024

C-C motif chemokine receptor-2 blockade ameliorates pulmonary hypertension in rats and synergizes with a pulmonary vasodilator.

Issue Release: 2024

A real-world pilot study assessing treatment satisfaction with avanafil in patients with erectile dysfunction.

Issue Release: 2024

Association of sildenafil use with age-related macular degeneration: a retrospective cohort study.

Issue Release: 2024

A multi-modal approach to investigate Desmodium gangeticum\'s influence on stress-induced male infertility: In vivo, in vitro, and in silico assessments.

Issue Release: 2024

Inonotus obliquus (Chaga) against HFD/STZ-induced glucolipid metabolism disorders and abnormal renal functions by regulating NOS-cGMP-PDE5 signaling pathway.

Issue Release: 2024

Isoliquiritigenin: a potential drug candidate for the management of erectile dysfunction.

Issue Release: 2024

Proceedings of PRINCETON IV: PDE5 inhibitors and cardiac health symposium.

Issue Release: 2024

Phosphodiesterase-5 Inhibitors and Dementia Risk: A Real-World Study.

Issue Release: 2024

The nitric oxide-soluble guanylate cyclase-cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase.

Issue Release: 2024

Variable temperature-nuclear magnetic resonance experiment and high-resolution MS/MS measurement of hydroxycarbodenafil, and its PDE5 inhibitory activity.

Issue Release: 2024

[Erectile dysfunction in the hypertensive patient].

Issue Release: 2024

What are the Challenges in Implementing Collaborative Care Models?

How are ADEs Detected and Reported?

How Can Technology Aid in Management?

Why is the Management of Chronic Conditions Important?

Why is Transitional Care Important in Pharma?

What are the Key Challenges?

What is the Future of the Pharmacy Profession?

What Types of Medications are Used?

What are Contract Research Organizations (CROs)?

How Can Technology Aid in Patient Education?

Partnered Content Networks

Relevant Topics